guselkumab; risankizumab; secukinumab; ustekinumab; acute heart infarction; allergy; arthralgia; article; candidiasis; connective tissue disease; controlled study; coronavirus disease 2019; diarrhea; drug efficacy; drug safety; drug substitution; drug withdrawal; flu like syndrome; follow up; headache; human; hypertension; infection; injection site reaction; musculoskeletal disease; psoriasis; psoriasis vulgaris; randomized controlled trial (topic); respiratory tract infection; rhinopharyngitis; systematic review; tinea capitis; upper respiratory tract infection